GOLD stage 1 COPD pharmacotherapy: big questions, few answers

European Respiratory Journal 2026

View at publisher
Authors: Helen O'Brien, Cormac McCarthy, Alessandro N. Franciosi
DOI: 10.1183/13993003.01948-2025
Cited by: 1
References: 27

Abstract

Shareable abstract Despite GOLD 1 accounting for roughly half of the 200–400 million people with COPD worldwide, randomised controlled trials supporting the routine use of pharmacotherapy in this group are lacking. Better, more considered studies are sorely needed.

Fields of Study & Subjects

Chronic Obstructive Pulmonary Disease (COPD) Research Respiratory and Cough-Related Research Inhalation and Respiratory Drug Delivery

Publication details

Journal / source
European Respiratory Journal
Publisher
European Respiratory Society (ERS)
Volume
67
Issue
6
Pages
2501948–2501948
Publication date
23 April 2026
Language
EN